Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty

  • Kim, Eun Young (Department of Pediatrics, Chosun University School of Medicine)
  • Received : 2014.08.26
  • Accepted : 2014.10.20
  • Published : 2015.01.10
Download PDF
⟨ Previous Next ⟩

Abstract

Gonadotropin-releasing hormone analogs (GnRHa) are widely used to treat central precocious puberty (CPP). The efficacy and safety of GnRHa treatment are known, but concerns regarding long-term complications are increasing. Follow-up observation results after GnRHa treatment cessation in female CPP patients up to adulthood showed that treatment (especially <6 years) was beneficial for final adult height relative to that of pretreated or untreated patients. Puberty was recovered within 1 year after GnRHa treatment discontinuation, and there were no abnormalities in reproductive function. CPP patients had a relatively high body mass index (BMI) at the time of CPP diagnosis, but BMI standard deviation score maintenance during GnRHa treatment seemed to prevent the aggravation of obesity in many cases. Bone mineral density decreases during GnRHa treatment but recovers to normal afterwards, and peak bone mass formation through bone mineral accretion during puberty is not affected. Recent studies reported a high prevalence of polycystic ovarian syndrome in CPP patients after GnRHa treatment, but it remains unclear whether the cause is the reproductive mechanism of CPP or GnRHa treatment itself. Studies of the psychosocial effects on CPP patients after GnRHa treatment are very limited. Some studies have reported decreases in psychosocial problems after GnRHa treatment. Overall, GnRHa seems effective and safe for CPP patients, based on long-term follow-up studies. There have been only a few long-term studies on GnRHa treatment in CPP patients in Korea; therefore, additional long-term follow-up investigations are needed to establish the efficacy and safety of GnRHa in the Korean population.

Keywords

References

  1. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-2. https://doi.org/10.1210/jcem-52-2-370
  2. The early detection of prcocious puberty is important [internet]. Seoul: Health Insurance Review & Assessment Service; c2013 [cited 2014 Jun 4]. Available from: http://www.hira.or.kr
  3. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973-8. https://doi.org/10.1210/jcem.84.6.5647
  4. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4. https://doi.org/10.1530/eje.0.1410140
  5. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-6. https://doi.org/10.1210/jcem.86.10.7915
  6. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarrevan de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13 Suppl 1:765-72. https://doi.org/10.1515/JPEM.2000.13.S1.765
  7. Kletter GB, Kelch RP. Clinical review 60: effects of gonadotropinreleasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994;79:331-4.
  8. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-9. https://doi.org/10.1210/jc.2007-0321
  9. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropinreleasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-17. https://doi.org/10.1210/jc.2009-0793
  10. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93:190-5. https://doi.org/10.1210/jc.2007-1216
  11. Kwon EB, Lee SJ, Cha M, Kim SY. Changes in the predicted adult height after gonadotropin-releasing hormone agonist treatment in girls with idiopathic true precocious puberty. Ann Pediatr Endocrinol Metab 2012;17:160-8. https://doi.org/10.6065/apem.2012.17.3.160
  12. Baek JW, Nam HK, Jin D, Oh YJ, Rhie YJ, Lee KH. Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2014;19:27-31. https://doi.org/10.6065/apem.2014.19.1.27
  13. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue: a comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997;47:54-61. https://doi.org/10.1159/000185432
  14. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135-47. https://doi.org/10.1093/humupd/dmh012
  15. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol (Oxf) 2002;56:297-302. https://doi.org/10.1046/j.1365-2265.2002.01488.x
  16. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and longterm follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415-23.
  17. Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639. https://doi.org/10.1186/1687-9856-2010-398639
  18. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-255:217-20. https://doi.org/10.1016/j.mce.2006.04.012
  19. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009;123:84-8. https://doi.org/10.1542/peds.2008-0146
  20. Frontini MG, Srinivasan SR, Berenson GS. Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2003;27:1398-404. https://doi.org/10.1038/sj.ijo.0802422
  21. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626-34. https://doi.org/10.1111/j.1365-2265.2004.02146.x
  22. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropinsuppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533-7. https://doi.org/10.1530/eje.0.1500533
  23. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;84:4583-90.
  24. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-8.
  25. Sorensen K, Mouritsen A, Mogensen SS, Aksglaede L, Juul A. Insulin sensitivity and lipid profiles in girls with central precocious puberty before and during gonadal suppression. J Clin Endocrinol Metab 2010;95:3736-44. https://doi.org/10.1210/jc.2010-0731
  26. Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L, Antoniazzi F, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 2010;93:1185-91. https://doi.org/10.1016/j.fertnstert.2008.11.016
  27. Soyka LA, Fairfield WP, Klibanski A. Clinical review 117: Hormonal determinants and disorders of peak bone mass in children. J Clin Endocrinol Metab 2000;85:3951-63.
  28. Scharla SH, Minne HW, Waibel-Treber S, Schaible A, Lempert UG, Wuster C, et al. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1990;70:1055-61. https://doi.org/10.1210/jcem-70-4-1055
  29. Saggese G, Bertelloni S, Baroncelli GI, Battini R, Franchi G. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr 1993;152:717-20. https://doi.org/10.1007/BF01953983
  30. Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropinreleasing hormone agonist treatment. J Clin Endocrinol Metab 1999;84:1992-6. https://doi.org/10.1210/jcem.84.6.5791
  31. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506-12. https://doi.org/10.1210/jcem.87.2.8202
  32. Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012;77:743-8. https://doi.org/10.1111/j.1365-2265.2012.04418.x
  33. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
  34. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. https://doi.org/10.1210/jc.2003-032046
  35. Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-96. https://doi.org/10.1210/jc.2006-2012
  36. Root AW, Moshang T Jr. Evolution of the hyperandrogenismpolycystic ovary syndrome from isosexual precocious puberty: report of two cases. Am J Obstet Gynecol 1984;149:763-7. https://doi.org/10.1016/0002-9378(84)90118-2
  37. Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 1995;133:403-6. https://doi.org/10.1530/eje.0.1330403
  38. Bridges NA, Cooke A, Healy MJ, Hindmarsh PC, Brook CG. Ovaries in sexual precocity. Clin Endocrinol (Oxf) 1995;42:135-40. https://doi.org/10.1111/j.1365-2265.1995.tb01853.x
  39. Chiavaroli V, Liberati M, D'Antonio F, Masuccio F, Capanna R, Verrotti A, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010;163:55-62. https://doi.org/10.1530/EJE-09-1102
  40. Waylen A, Wolke D. Sex 'n' drugs 'n' rock 'n' roll: the meaning and social consequences of pubertal timing. Eur J Endocrinol 2004;151 Suppl 3:U151-9. https://doi.org/10.1530/eje.0.151U151
  41. Johansson T, Ritzen EM. Very long-term follow-up of girls with early and late menarche. Endocr Dev 2005;8:126-36. https://doi.org/10.1159/000084098
  42. Ehrhardt AA, Meyer-Bahlburg HF, Bell JJ, Cohen SF, Healey JM, Stiel R, et al. Idiopathic precocious puberty in girls: psychiatric follow-up in adolescence. J Am Acad Child Psychiatry 1984;23:23-33. https://doi.org/10.1097/00004583-198401000-00004
  43. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Dooms L, Malvaux P, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during longacting triptorelin therapy. Acta Paediatr 1997;86:808-15.
  44. Mul D, Versluis-den Bieman HJ, Slijper FM, Oostdijk W, Waelkens JJ, Drop SL. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr 2001;90:965-71. https://doi.org/10.1111/j.1651-2227.2001.tb01349.x
  45. Kim EY, Lee MI. Psychosocial aspects in girls with idiopathic precocious puberty. Psychiatry Investig 2012;9:25-8. https://doi.org/10.4306/pi.2012.9.1.25

Cited by

  1. Overview and treatment of precocious puberty vol.58, pp.12, 2015, https://doi.org/10.5124/jkma.2015.58.12.1138
  2. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty vol.38, pp.11, 2017, https://doi.org/10.15537/smj.2017.11.21187
  3. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment vol.32, pp.3, 2017, https://doi.org/10.3346/jkms.2017.32.3.475
  4. 특발성 성조숙증으로 진단받은 환아 2례에 대한 증례보고 vol.31, pp.1, 2015, https://doi.org/10.7778/jpkm.2017.31.1.074
  5. Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty vol.22, pp.4, 2017, https://doi.org/10.6065/apem.2017.22.4.259
  6. Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature vol.90, pp.3, 2015, https://doi.org/10.23750/abm.v90i3.8736
  7. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium vol.91, pp.6, 2015, https://doi.org/10.1159/000501336
  8. Use of gonadotropin-releasing hormone analogs in children vol.33, pp.4, 2021, https://doi.org/10.1097/mop.0000000000001026
  9. Hormone-producing ovarian tumors in children (a clinical case of managing a patient with a granulosa cell tumor of the juvenile type) vol.27, pp.5, 2015, https://doi.org/10.17116/repro20212705148
  10. Implications for gender and education research arising out of changing ideas about gender vol.33, pp.5, 2015, https://doi.org/10.1080/09540253.2020.1798361